Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Triplet Might Offer Arcus An Edge

 
• By Andrew McConaghie
  
Arcus Biosciences
Founded in 2015, Arcus is hoping anti-TIGIT candidate domvanalimab will be its big breakthrough. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip